I first demonstrate how a GLM can be employed and how the support for the predictors can be measured using influenza A/H5N1 in Egypt as an example. Secondly, I compare the GLM framework to two alternative frameworks of Bayesian phylogeography: one that uses an advanced computational technique and one that does not. For this assessment, I model the diffusion of influenza A/H3N2 in the United States during the 2014-15 flu season with five methods encapsulated by the three frameworks. I summarize metrics of the phylogenies created by each and demonstrate their reproducibility by performing analyses on several random sequence samples under a variety of population growth scenarios. Next, I demonstrate how discretization of the location trait for a given sequence set can influence phylogenies and support for predictors. That is, I perform several GLM analyses on a set of sequences and change how the sequences are pooled, then show how aggregating predictors at four levels of spatial resolution will alter posterior support. Finally, I provide a solution for researchers that wish to use the GLM framework but may be deterred by the tedious file-manipulation requirements that must be completed to do so. My pipeline, which is publicly available, should alleviate concerns pertaining to the difficulty and time-consuming nature of creating the files necessary to perform GLM analyses. This dissertation expands the knowledge of Bayesian phylogeographic GLMs and will facilitate the use of this framework, which may ultimately reveal the variables that drive the spread of pathogens.
Researchers have iterated that the future of synthetic biology and biotechnology lies in novel consumer applications of crossing biology with engineering. However, if the new biology's future is to be sustainable, early and serious efforts must be made towards social sustainability. Therefore, the crux of new applications of synthetic biology and biotechnology is public understanding and acceptance. The RASVaccine is a novel recombinant design not found in nature that re-engineers a common bacteria ( Salmonella) to produce a strong immune response in humans. Synthesis of the RASVaccine has the potential to improve public health as an inexpensive, non-injectable product. But how can scientists move forward to create a dialogue of creating a 'common sense' of this new technology in order to promote social sustainability? This paper delves into public issues raised around these novel technologies and uses the RASVaccine as an example of meeting the public with a common sense of its possibilities and limitations.